NeoGenomics, Inc. (NEO)
- Previous Close
13.85 - Open
13.91 - Bid 14.11 x 400
- Ask 14.18 x 400
- Day's Range
13.68 - 14.35 - 52 Week Range
11.03 - 21.22 - Volume
787,712 - Avg. Volume
905,165 - Market Cap (intraday)
1.805B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.70 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.55
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
www.neogenomics.com2,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NEO
Performance Overview: NEO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEO
Valuation Measures
Market Cap
1.81B
Enterprise Value
2.00B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.00
Price/Book (mrq)
1.92
Enterprise Value/Revenue
3.38
Enterprise Value/EBITDA
-113.69
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.87%
Return on Assets (ttm)
-3.50%
Return on Equity (ttm)
-9.07%
Revenue (ttm)
591.64M
Net Income Avi to Common (ttm)
-87.97M
Diluted EPS (ttm)
-0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
415.2M
Total Debt/Equity (mrq)
64.97%
Levered Free Cash Flow (ttm)
289.62k
Research Analysis: NEO
Company Insights: NEO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NEO
NEO: What does Argus have to say about NEO?
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetNEO: Lowering target price to $15.00
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetNEO: What does Argus have to say about NEO?
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetNEO: What does Argus have to say about NEO?
NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target